본문 바로가기
KERD
논문KCI 등재

Tumor-associated autoantibodies as diagnostic and prognostic biomarkers

박영일|조은위|Chang-Kyu Heo
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2012.12|BMB Reports|제45권 제12호|pp. 677-685

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

BiomarkerDiagnosticPrognosticTumor-associated autoantibodyTumor-associated autoantigen
주제분류화학

초록

In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are undetectable in sera at the early stage of tumorigenesis,the nature of an antibody amplification response to antigens makes tumor-associated autoantibodies as promising early biomarkers in cancer diagnosis. Moreover, the recent development of proteomic techniques that make neo-epitopes of tumor-associated autoantigens discovered concomitantly has opened a new area of ‘immuno-proteomics’, which presents tumor-associated autoantibody signatures and confers information to redefine the process of tumorigenesis. In this article, the strategies recently used to identify and validate serum autoantibodies are outlined and tumor-associated antigens suggested until now as diagnostic/prognostic biomarkers in various tumor types are reviewed. Also, the meaning of autoantibody signatures and their clinical utility in personalized medicine are discussed. [BMB Reports 2012;45(12): 677-685]

Abstract

In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are undetectable in sera at the early stage of tumorigenesis,the nature of an antibody amplification response to antigens makes tumor-associated autoantibodies as promising early biomarkers in cancer diagnosis. Moreover, the recent development of proteomic techniques that make neo-epitopes of tumor-associated autoantigens discovered concomitantly has opened a new area of ‘immuno-proteomics’, which presents tumor-associated autoantibody signatures and confers information to redefine the process of tumorigenesis. In this article, the strategies recently used to identify and validate serum autoantibodies are outlined and tumor-associated antigens suggested until now as diagnostic/prognostic biomarkers in various tumor types are reviewed. Also, the meaning of autoantibody signatures and their clinical utility in personalized medicine are discussed. [BMB Reports 2012;45(12): 677-685]

참고문헌 (90)

  1. Baldwin, R. W., "Tumour-specific immunity against spontaneous rat tumours", Int. J. Cancer, 1, pp.257~264 (1966)
  2. Anderson, K. S., "The sentinel within: exploiting the immune system for cancer biomarkers", J. Proteome Res., 4, pp.1123~1133 (2005)
  3. Caron, M., "Cancer immunomics using autoantibody signaturesfor biomarker discovery", Mol. Cell Proteomics, 6, pp.1115~1122 (2007)
  4. Gunawardana, C. G., "High throughput proteomic strategies for identifying tumour- associated antigens", Cancer Lett., 249, pp.110~119 (2007)
  5. Chong Hyun Won, "Comparative secretome analysis of human follicular dermal papilla cells and fibroblasts using shotgun proteomics", BMB Reports, 45(4), pp.253~258 (2012), 생화학분자생물학회[DOI]
  6. Jeong-Gu Kang, "Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer", BMB Reports, 44(12), pp.765~771 (2011), 생화학분자생물학회
  7. Zhang, J. Y., "Enhancement of antibody detection in cancer using panel of recombinant tumor- associated antigens", Cancer Epidemiol. Biomarkers Prev., 12, pp.136~143 (2003)
  8. Murphy, M. A., "Assessment of the humoral immune response to cancer", J. Proteomics, 75, pp.4573~4579 (2012)
  9. Tan, H. T., "Serum autoantibodies as biomarkers for early cancer detection", FEBS J., 276, pp.6880~6904 (2009)
  10. Chaput, N., "The Janus face of dendritic cells in cancer", Oncogene, 27, pp.5920~5931 (2008)
  11. Whiteside, T. L., "The tumor microenvironment and its role in promoting tumor growth", Oncogene, 27, pp.5904~5912 (2008)
  12. Dunn, G. P., "Cancer immunoediting: from immunosurveillance to tumor escape", Nat. Immunol., 3, pp.991~998 (2002)
  13. Dunn, G. P., "The three Es of cancer immunoediting", Annu. Rev. Immunol., 22, pp.329~360 (2004)
  14. Zitvogel, L., "Cancer despite immunosurveillance: immunoselection and immunosubversion", Nat. Rev. Immunol., 6, pp.715~727 (2006)
  15. McGilvray, R. W., "NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting", Clin. Cancer Res., 15, pp.6993~7002 (2009)
  16. Waldhauer, I., "NK cells and cancer immunosurveillance", Oncogene, 27, pp.5932~5943 (2008)
  17. Guerra, N., "NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy", Immunity, 28, pp.571~580 (2008)
  18. Salavoura, K., "Development of cancer in patients with primaryimmunodeficiencies", Anticancer Res., 28, pp.1263~1269 (2008)
  19. Yigit, R., "Ovarian cancer creates a suppressive microenvironmentto escape immune elimination", Gynecol. Oncol., 117, pp.366~372 (2010)
  20. Lechner, M., "Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin", Semin. Cancer Biol., 15, pp.277~289 (2005)
  21. Ran, Y., "Profiling tumor-associated autoantibodies for the detection of colon cancer", Clin. Cancer Res., 14, pp.2696~2700 (2008)
  22. Sahin, U., "Human neoplasms elicit multiple specific immune responses in the autologous host", Proc. Natl. Acad. Sci. U.S.A., 92, pp.11810~11813 (1995)
  23. Stockert, E., "A survey of the humoral immune response of cancer patients to a panel of human tumor antigens", J. Exp. Med., 187, pp.1349~1354 (1998)
  24. Chen, Y., "Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection", Int. J. Oncol., 30, pp.1137~1144 (2007)
  25. Gure, A. O., "Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer", Proc. Natl. Acad. Sci. U.S.A., 97, pp.4198~4203 (2000)
  26. Fernandez-Madrid, F., "Autoantibodies to annexin xi-a and other autoantigens in the diagnosis of breast cancer", Cancer Res., 64, pp.5089~5096 (2004)
  27. Klade, C. S., "Identification of tumor antigens in renal cell carcinoma by serological proteome analysis", Proteomics, 1, pp.890~898 (2001)
  28. Canelle, L., "An efficient proteomics-based approach for the screening of autoantibodies", J. Immunol. Methods, 299, pp.77~89 (2005)
  29. Hardouin, J., "Usefulness of autoantigens depletion to detect autoantibody signatures by multiple affinity protein profiling", J. Sep. Sci., 30, pp.352~358 (2007)
  30. Ehrlich, J. R., "The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling", Nat. Protoc., 1, pp.452~460 (2006)
  31. Miller, J. C., "Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers", Proteomics, 3, pp.56~63 (2003)
  32. Qin, S., "Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling", Proteomics, 6, pp.3199~3209 (2006)
  33. Bouwman, K., "Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity", Proteomics, 3, pp.2200~2207 (2003)
  34. Kijanka, G., "Protein arrays as tools for serum autoantibody marker discovery in cancer", J. Proteomics, 72, pp.936~944 (2009)
  35. Nam, M. J., "Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3", Proteomics, 3, pp.2108~2115 (2003)
  36. Tan, E. M., "Autoantibodies to tumor- associated antigens: reporters from the immune system", Immunol. Rev., 222, pp.328~340 (2008)
  37. Desmetz, C., "Autoantibody signatures: progress and perspectives forearly cancer detection", J. Cell Mol. Med., 15, pp.2013~2024 (2011)
  38. Fernandez Madrid, F, "Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis", Cancer Lett., 230, pp.187~198 (2005)
  39. Cocucci, E., "Shedding microvesicles: artefacts no more", Trends Cell Biol., 19, pp.43~51 (2009)
  40. D'Souza-Schorey, C., "Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers", Genes Dev., 26, pp.1287~1299 (2012)
  41. Nesterova, M., "Autoantibody biomarker opens a new gateway for cancer diagnosis", Biochim. Biophys. Acta., 1762, pp.398~403 (2006)
  42. Tan, E. M., "Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis", J. Clin. Invest., 108, pp.1411~1415 (2001)
  43. Montgomery, R. B., "Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase", Cancer Res., 65, pp.650~656 (2005)
  44. Casal, J. I., "Identification of cancer autoantigens in serum: toward diagnostic", prognostic testing?, 2010, pp.14, 149~154
  45. Hanash, S., "Harnessing immunity for cancer marker discovery", Nat. Biotechnol., 21, pp.37~38 (2003)
  46. Lu, H., "Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer", J. Proteome Res., 7, pp.1388~1394 (2008)
  47. Murray, A., "Technical validation of an autoantibody test for lung cancer", Ann. Oncol., 21, pp.1687~1693 (2010)
  48. Jaras, K., "Autoantibodies in cancer: prognostic biomarkers and immune activation", Expert Rev. Proteomics, 8, pp.577~589 (2011)
  49. Sotiriou, C., "Gene-expression signatures in breast cancer", N. Engl. J. Med., 360, pp.790~800 (2009)
  50. Kobold, S., "Prognostic and diagnostic value of spontaneous tumor-related antibodies", Clin. Dev. Immunol., 2010, pp.721531~ (2010)
  51. Angelopoulou, K., "Detection of the TP53 tumour suppressor gene product and p53 auto- antibodies in the ascites of women with ovarian cancer", Eur. J. Cancer, 33, pp.115~121 (1997)
  52. Tangkijvanich, P., "Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma", Asian Pac. J. Allergy Immunol., 18, pp.237~243 (2000)
  53. Tang, R., "Humoral response to p53 in human colorectal tumors: a prospective study of 1, 209 patients", Int. J. Cancer, 94, pp.859~863 (2001)
  54. Knutson, K. L., "Tumor antigen-specific T helper cells in cancer immunity and immunotherapy", Cancer Immunol. Immunother., 54, pp.721~728 (2005)
  55. Rosenberg, S. A., "Cancer vaccines based on the identification of genes encoding cancer regression antigens", Immunol. Today, 18, pp.175~182 (1997)
  56. Fuessel, S., "Vaccination of hormone-refractory prostate cancer patients with peptide cocktail- loaded dendritic cells: results of a phase I clinical trial", Prostate, 66, pp.811~821 (2006)
  57. Slovin, S. F., "A polyvalent vaccine for high-risk prostate patients: "are more antigens better?", Cancer Immunol. Immunother., 56, pp.1921~1930 (2007)
  58. Neller, M. A., "Antigens for cancer immunotherapy", Semin. Immunol., 20, pp.286~295 (2008)
  59. Liu, W., "Autoantibodies to tumor-associated antigens as biomarkersin cancer immunodiagnosis", Autoimmun. Rev., 10, pp.331~335 (2011)
  60. Taylor, B. S., "Humoral response profiling reveals pathways to prostate cancer progression", Mol. Cell Proteomics, 7, pp.600~611 (2008)
  61. Zayakin, P., "Tumor-associated autoantibody signature for the early detection of gastric cancer", Int. J. Cancer, 132, pp.137~147
  62. Cheng, Y., "Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma", Clin. Transl. Oncol. (2012)
  63. Yang, Z., "Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: Application to the sensitive and specific detection of tumor markers from breast cancer sera", Biosens Bioelectron, 40, pp.385~392
  64. Shan, Q., "A cancer", testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer, pp.328, 160~167
  65. Lacombe, J., "Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers", Int. J. Cancer (2012)
  66. Lopez-Arias, E., "Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early- stage breast cancer", Electrophoresis, 33, pp.2130~2137 (2012)
  67. Yao, Y., "Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis", Biochem. Biophys. Res. Commun., 423, pp.613~619 (2012)
  68. Shao, Q., "Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma", Int. J. Oncol., 41, pp.1061~1067 (2012)
  69. Nomura, F., "Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma", Biochem. Biophys. Res. Commun., 421, pp.837~843 (2012)
  70. Zhang, B., "Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma", Biomarkers, 17, pp.372~378 (2012)
  71. Chapman, C. J., "EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays", Tumour Biol., 33, pp.1319~1326 (2012)
  72. Tong, Y. Q., "BMI-1 autoantibody as a new potential biomarker for cervical carcinoma", PLoS One, 6, pp.e27804~ (2011)
  73. Li, J., "Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer", Scand. J. Immunol., 75, pp.342~349 (2012)
  74. Chang, W., "Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma", Clin. Cancer Res., 17, pp.5715~5724 (2011)
  75. Chen, J. S., "Detection of autoantibodies against Rabphilin-3A-like protein as a potential biomarker in patient's sera of colorectal cancer", Clin. Chim. Acta., 412, pp.1417~1422 (2011)
  76. Xie, C., "A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases", J. Transl. Med., 9, pp.43~ (2011)
  77. Zhou, J. H., "Autoantibodies against MMP-7 as a novel diagnosticbiomarker in esophageal squamous cell carcinoma", WorldJ. Gastroenterol., 17, pp.1373~1378 (2011)
  78. Fan, C. W., "Identification of SEC61beta and its autoantibody as biomarkers for colorectal cancer", Clin. Chim. Acta., 412, pp.887~893 (2011)
  79. Babel, I., "Identification of MST1", STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays, 2011, pp.10, ~
  80. Chapman, C. J., "Immunobiomarkers in small cell lung cancer: potential early cancer signals", Clin. Cancer Res., 17, pp.1474~1480 (2011)
  81. Anderson, K. S., "Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer", J. Proteome Res., 10, pp.85~96 (2011)
  82. Tomaino, B., "Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer", J. Proteome Res., 10, pp.105~112 (2011)
  83. Budiu, R. A., "Soluble MUC1 and serum MUC1- specific antibodies are potential prognostic biomarkers for platinum- resistant ovarian cancer", Cancer Immunol. Immunother., 60, pp.975~984 (2011)
  84. Blixt, O., "Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis", Breast Cancer Res., 13, pp.R25~ (2011)
  85. Heubner, M., "EpCAM-autoantibody levels in the course of disease of ovarian cancer patients", Med. Oncol., 28, pp.626~630 (2011)
  86. Ait-Tahar, K., "Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk", Blood, 115, pp.3314~3319 (2010)
  87. Dong, J., "Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma", J. Transl. Med., 8, pp.81~ (2010)
  88. Anderson, K. S., "p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer", Cancer Epidemiol. Biomarkers Prev., 19, pp.859~868 (2010)
  89. Gnjatic, S., "Seromic profiling of ovarian and pancreatic cancer", Proc. Natl. Acad. Sci. U.S.A., 107, pp.5088~5093 (2010)
  90. Heller, A., "Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer", Cancer Immunol. Immunother., 59, pp.1389~1400 (2010)

관련 논문AI추천

Comprehensive Identification of Tumor-associated Antigens via Isolation of Human Monoclonal Antibodies that may be TherapeuticYoshikazu Kurosawa대한면역학회 · Immune Network2009 · 제9권 제1호상피성 난소암 환자에서 혈청 내 p53 자가 항체 발현과 예후평가와의 관계고석봉, 박정신대한산부인과학회 · Obstetrics & Gynecology Science2008 · 제51권 제4호Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer강정구, 고정헌, 김용삼생화학분자생물학회 · BMB Reports2011 · 제44권 제12호The Path to Clinical Proteomics Research: Integration of Proteomics, Genomics, Clinical Laboratory and Regulatory ScienceEmily S. Boja, Henry Rodriguez대한진단검사의학회 · Annals of Laboratory Medicine2011 · 제31권 제2호Glycoscience aids in biomarker discovery안현주, Serenus Hua생화학분자생물학회 · BMB Reports2012 · 제45권 제6호전립선암 진단을 위한 바이오마커 패널김영희, 조정기대한의용생체공학회 · 의공학회지2017 · 제38권 제5호

이 간행물의 다른 논문 (11건)

Mouse genetics: Catalogue and scissors김진수, 성제경, 이한웅, Young Hoon Sung, 백인정pp. 686-692Structure and catalytic mechanism of human protein tyrosine phosphatome류성언, 김승준pp. 693-699Involvement of protein tyrosine phosphatases in adipogenesis: New anti-obesity targets?이상철, 김원곤, 배광희pp. 700-706Roles of cysteine residues in the inhibition of human glutamate dehydrogenase by palmitoyl-CoAHyo Jeong Son, Seung Cheol Ha, Eun Young Hwang, 조성우, 안지인, 김은아, 최수영pp. 707-712Ganglioside GM1 influences the proliferation rate of mouse induced pluripotent stem cellsGislain Moussavou, 김지수, 김선욱, 장규태, 이정웅, 추영국, 고기성, 고기남, Kyung-A Hwang, 임맑음, 유재성, Ju-Taek Lee, Hyun-Ki Min, Yoon-Ju Na, Su-Bin Lee, Eun-Jeong Jeongpp. 713-718
원문 보기